Hans‐Jürgen Stellbrink

Author

Also Known As

Christiane Moecklinghoff, Christoph Boesecke, Collins, S.E., Das, M., H J Stellbrink, H. -J. Stellbrink, H. J. Stellbrink, H.-J. STELLBRINK, H.-J. Stellbrink, H.J. Stellbrink

141

Publications

8.5K

Citations

H-Index

Concepts

All Affiliations

Infektionsmedizinisches Centrum Hamburg Universität Hamburg University Medical Center Hamburg-Eppendorf Eppendorf (Germany)Medizinische Hochschule Hannover

About

Hans‐Jürgen Stellbrink is an author at Infektionsmedizinisches Centrum Hamburg specializing in hiv, medicine, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2.1K
2	Public Health	4	4	618
3	Epidemiology	4	4	792
4	Cell Biology	1	1	163
5	Gastroenterology	1	1	24

Hans‐Jürgen Stellbrink

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study Alison Rodger, Valentina Cambiano, Tina Bruun, The Lancet	2019	966
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink, The Lancet Week ResultsTreatment And PreventionHuman RetrovirusAntiviral TherapyDolutegravir Versus Raltegravir	2013	537
Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study Hans‐Jürgen Stellbrink, Chloe Orkin, José Ramón Arribas, Clinical Infectious Diseases	2010	409
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink, New England Journal of Medicine	2022	270
Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study Elchonon M. Berkowitz, Graeme Moyle, Hans‐Jürgen Stellbrink, The Journal of Infectious Diseases	2014	208
The Unenlarged Lymph Nodes of HIV-1–infected, Asymptomatic Patients with High CD4 T Cell Counts Are Sites for Virus Replication and CD4 T Cell Proliferation. The Impact of Highly Active Antiretroviral Therapy Klara Tenner‐Racz, Hans‐Jürgen Stellbrink, Jan van Lunzen, The Journal of Experimental Medicine	1998	197
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial Jean‐Michel Molina, Douglas Ward, Indira Brar, The Lancet HIV Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirology	2018	192
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe Patrick Ingiliz, Thomas Martin, Alison Rodger, Journal of Hepatology Sexual HealthViral PersistenceSpontaneous Clearance RatesViral HepatitisWestern Europe	2016	173
Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy Mikuláš Popovič, Klara Tenner‐Racz, Colleen Pelser, Proceedings of the National Academy of Sciences Viral ReplicationImmunologyImmunodominanceHiv-1 PersistenceViral Persistence	2005	163

Page 1